QuidelOrtho Corporation was formed in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The company operates through four primary business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. Its product portfolio includes the VITROS dry-slide chemistry analyzers, QuickVue rapid lateral-flow tests, and Sofia fluorescent immunoassay systems. QuidelOrtho serves a diverse customer base, including hospitals, reference laboratories, blood banks, and urgent care clinics across North America, EMEA, and other international markets. The company's business model heavily relies on the recurring sale of disposable assays, reagents, and testing consumables used on its installed base of diagnostic instruments.
